AI Color-Coding Guides First Live Brain Tumor Surgery in London

Rhys Hibbert went into surgery at real risk of losing his sight. The 48-year-old from Bedfordshire had a tumor pressing on his pituitary gland, a region of the brain where nerves controlling vision sit within a millimeter of critical blood vessels. A single misjudged cut there can mean permanent blindness.

In May 2026, surgeons at the National Hospital for Neurology and Neurosurgery in London removed that tumor with help from an AI system that had never before been used on a live patient in an operating room. It marks what the hospital describes as the first operation of its kind anywhere in the world.

The technology, built by researchers at University College London's Hawkes Institute, processes live video from operating room cameras and highlights delicate neural structures in distinct colors as the surgery unfolds. That real-time color-coding gives the surgical team a continuously updated map of exactly where nerves and vessels lie, reducing the guesswork in a procedure where anatomy can be difficult to distinguish by eye alone.

The system had already been tested as a research tool inside the same hospital, but only in observational settings, never as an active guide during a real procedure. This case shifted it from the lab bench to the operating table.

Surgeons removed Hibbert's tumor in full and preserved his vision. He has since said the operation spared him from near-certain blindness, a claim that lines up with the surgical risk profile doctors describe for this type of tumor.

An error of even one millimeter in this region can cost a patient their sight.

That margin is what makes the case notable beyond a single successful outcome. Pituitary surgery has long depended on surgeons interpreting subtle visual cues under a microscope, with little room for correction once a cut is made. A system that flags nerve and vessel boundaries in real time offers a second layer of judgment precisely where human error carries the highest cost.

It remains a single procedure, not a clinical trial, and there is no data yet on how the tool performs across a larger patient population or different tumor types. But as a proof of concept, moving color-coded AI guidance from a research add-on to a live decision-making aid in one of neurosurgery's most delicate operations is a concrete step that other centers doing similar procedures will likely watch closely.